N-terminal GST tagged, recombinant human cKit, amino acids 544 - end containing the V654A mutation. Co-ordinates encompass the cytoplasmic domain (544-976) according in Swiss Prot P10721. V654A is an acquired resistance mutation which has been found in patients with gastrointestinal stromal tumours (GISTs) undergoing treatment with Imatinib. The V654A mutation is strongly correlated with imatinib resistance and rapid progession of GISTs. (Chen LL et al., Cancer Research, (2004); 64:5913-5919).

recombinant protein expressed in Sf21 cells

Research Category
Metabolism|Inflammation & Immunology

Research Sub Category
Obesity|Metabolic Disorders|Osteoporosis|Arthritis

V654A is an acquired resistance mutation found in patients with gastrointestinal stromal tumours (GISTs) undergoing treatment with Imatinib. The V654A mutation is strongly correlated with imatinib resistance & rapid progession of GISTs.

Format: Purified using glutathione-agarose. Purity 99% by SDS-PAGE and Coomassie blue staining.

Stable for 6 months at -70 °C from date of shipment. For maximum recovery of product, centrifuge original vial prior to removing the cap.
Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled

Routinely evaluated by phosphorylation of 250 μM GGMEDIYFEFMGGKKK.
Purity was assessed by SDS-PAGE and Coomassie blue staining using 3 μg of active cKit (V654A).

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial